FDA approves first treatment for Pediatric MS

[Webdog]

https://www.nationalmssociety.org/About-the-Society/News/FDA-Expands-Use-of-Gilenya®-(fingolimod)-for-Child

(bolding in original)

“As the first therapy specifically approved to treat children and teens with MS, this is a major milestone,” said Kathy Costello, MS, ANP-BC, MSCN, Associate Vice President of Healthcare Access at the National MS Society.

“The Society has been working on this issue for more than a decade, creating awareness and consistency around the diagnosis and care of children with MS,” said Cyndi Zagieboylo, President and CEO of the National MS Society. “We are a global leader in this field and are pleased to see the Society’s early and fundamental work helped lay the groundwork for this important breakthrough.”

The U.S. Food and Drug Administration has approved Gilenya® (fingolimod, Novartis AG) for use in the treatment of children and adolescents 10 years of age or older with relapsing MS, making it the first therapy approved for the treatment of pediatric multiple sclerosis.